Edwards Lifesciences Operating Margin 2010-2022 | EW
Current and historical operating margin for Edwards Lifesciences (EW) over the last 10 years. The current operating profit margin for Edwards Lifesciences as of December 31, 2022 is 28.81%.
| Edwards Lifesciences Operating Margin Historical Data |
| Date |
TTM Revenue |
TTM Operating Income |
Operating Margin |
| 2022-12-31 |
$5.38B |
$1.75B |
32.50% |
| 2022-09-30 |
$5.36B |
$1.68B |
31.23% |
| 2022-06-30 |
$5.36B |
$1.66B |
31.06% |
| 2022-03-31 |
$5.36B |
$1.75B |
32.57% |
| 2021-12-31 |
$5.23B |
$1.69B |
32.30% |
| 2021-09-30 |
$5.10B |
$1.67B |
32.72% |
| 2021-06-30 |
$4.93B |
$1.64B |
33.19% |
| 2021-03-31 |
$4.48B |
$0.92B |
20.63% |
| 2020-12-31 |
$4.39B |
$0.90B |
20.45% |
| 2020-09-30 |
$4.37B |
$0.86B |
19.62% |
| 2020-06-30 |
$4.32B |
$0.79B |
18.35% |
| 2020-03-31 |
$4.48B |
$1.23B |
27.45% |
| 2019-12-31 |
$4.35B |
$1.15B |
26.38% |
| 2019-09-30 |
$4.15B |
$0.83B |
20.01% |
| 2019-06-30 |
$3.97B |
$0.79B |
19.82% |
| 2019-03-31 |
$3.82B |
$0.77B |
20.15% |
| 2018-12-31 |
$3.72B |
$0.75B |
20.11% |
| 2018-09-30 |
$3.64B |
$1.06B |
29.13% |
| 2018-06-30 |
$3.55B |
$1.04B |
29.24% |
| 2018-03-31 |
$3.45B |
$1.04B |
30.02% |
| 2017-12-31 |
$3.44B |
$1.09B |
31.74% |
| 2017-09-30 |
$3.32B |
$0.96B |
28.86% |
| 2017-06-30 |
$3.23B |
$0.92B |
28.58% |
| 2017-03-31 |
$3.15B |
$0.89B |
28.25% |
| 2016-12-31 |
$2.96B |
$0.78B |
26.43% |
| 2016-09-30 |
$2.87B |
$0.79B |
27.46% |
| 2016-06-30 |
$2.74B |
$0.75B |
27.27% |
| 2016-03-31 |
$2.60B |
$0.68B |
26.14% |
| 2015-12-31 |
$2.49B |
$0.64B |
25.78% |
| 2015-09-30 |
$2.44B |
$0.62B |
25.32% |
| 2015-06-30 |
$2.43B |
$0.59B |
24.34% |
| 2015-03-31 |
$2.39B |
$0.56B |
23.60% |
| 2014-12-31 |
$2.32B |
$0.49B |
21.23% |
| 2014-09-30 |
$2.24B |
$0.47B |
21.03% |
| 2014-06-30 |
$2.13B |
$0.45B |
21.00% |
| 2014-03-31 |
$2.07B |
$0.46B |
21.97% |
| 2013-12-31 |
$2.05B |
$0.47B |
23.12% |
| 2013-09-30 |
$2.02B |
$0.49B |
24.16% |
| 2013-06-30 |
$1.97B |
$0.48B |
24.19% |
| 2013-03-31 |
$1.94B |
$0.45B |
23.03% |
| 2012-12-31 |
$1.90B |
$0.42B |
22.12% |
| 2012-09-30 |
$1.82B |
$0.36B |
20.01% |
| 2012-06-30 |
$1.78B |
$0.33B |
18.44% |
| 2012-03-31 |
$1.73B |
$0.31B |
17.77% |
| 2011-12-31 |
$1.68B |
$0.30B |
17.87% |
| 2011-09-30 |
$1.64B |
$0.29B |
17.92% |
| 2011-06-30 |
$1.58B |
$0.30B |
19.09% |
| 2011-03-31 |
$1.51B |
$0.30B |
19.85% |
| 2010-12-31 |
$1.45B |
$0.29B |
19.70% |
| 2010-09-30 |
$1.40B |
$0.27B |
19.19% |
| 2010-06-30 |
$1.38B |
$0.26B |
18.78% |
| 2010-03-31 |
$1.35B |
$0.25B |
18.37% |
| 2009-12-31 |
$1.32B |
$0.24B |
18.07% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Instruments Manufacturing |
$50.772B |
$5.382B |
|
Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
|
